Stevens-Johnson syndrome and toxic epidermal necrolysis: A review of treatment options

Dermatologic Therapy

Volumn 24, Issue 2, 2011, Pages 207-218

  Worswick, Scott ^a   Cotliar, Jonathan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

IVIG; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; IMMUNOGLOBULIN G; INFLIXIMAB; METHYLPREDNISOLONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; HISTOPATHOLOGY; MORTALITY; PATHOPHYSIOLOGY; PLASMAPHERESIS; SCORING SYSTEM; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EPIDERMAL NECROLYSIS, TOXIC; HUMANS; SKIN; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME;

EID: 79952766052     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2011.01396.x     Document Type: Article

References (76)

1. Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin 2000: 18 (3): 485-495. (Pubitemid 30640151)
2. Palmieri T, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in US burn centers at the end of the twentieth century. J Burn Care Rehabil 2002: 23: 87-96. (Pubitemid 34242508)
3. Bastuji-Garin S, Fouchard N, Betocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000: 115: 149-153. (Pubitemid 30637181)
4. Pereira F, Mudgil A, Rosmarin D. Toxic epidermal necrolysis. J Am Acad Dermatol 2007: 56: 181-200. (Pubitemid 46074234)
5. Wehrli P, Viard I, Bullani R, et al. Death receptors in cutaneous biology and disease. J Invest Dermatol 2000: 115: 141-148. (Pubitemid 30637180)
6. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998: 352 (9140): 1586-1589. (Pubitemid 28515243)
7. Paquet P, Paquet F, Al Saleh W, et al. Immunregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol 2000: 22: 413-417.
8. Khalili B, Bahna S. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 2006: 97 (3): 272-280.
9. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J All Clin Immunol 2004: 114 (5): 1209-1215. (Pubitemid 39469167)
10. Kamanabroo D, Schmitz-Landgraf W, Czarnetzki B. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985: 121: 1548-1549. (Pubitemid 16202174)
11. Bolognia J, Jorizzo J, Rapini R. Dermatology. London: Elsevier, 2003: 291-299.
12. Blanca M, Romano A, Torres MJ, et al. Update on the evaluation of hypersensitivity reactions to beta-lactams. Allergy 2009: 64 (2): 183-193.
13. Mayorga C, Sanz ML, Gamboa PM, et al. In vitro diagnosis of immediate allergic reactions to drugs: an update. J Investig Allergol Clin Immunol 2010: 20: 103-109.
14. Schulz J, Sheridan RL, Ryan CM, et al. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000: 21: 199-204. (Pubitemid 30396349)
15. Shammas M, Edward C, Sarkar J, et al. Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. Am J Ophthamology 2010: 149: 203-213.
16. Patterson R, Miller M, Kaplan M, et al. Effectiveness of early therapywith corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy 1994: 73 (1): 27-34. (Pubitemid 24217545)
17. Kakourou T, Klontza D, Soteropoulou F, et al. Corticosteroid treatment of erythema multiforme major (Stevens- Johnson syndrome) in children. Eur J Pediatr 1997: 156: 90-93. (Pubitemid 27049148)
18. Tripathi A, Ditto A, Grammer L, et al. Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc 2000: 21: 101-105.
19. Hynes A, Kafkala C, Daoud Y, et al. Controversy in the use of high dose systemic steroids in the acute care of patients with Stevens-Johnson syndrome. Int J Ophthamol Clin 2005: 45 (4): 25-48. (Pubitemid 41546822)
20. Yamane Y, Aihara M, Tatewaki S, et al. Analysis of treatments and deceased cases of severe adverse drug reactions - analysis of 46 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Jpn J Allergol 2009: 58: 537-547.
21. Criton S, Devi K, Sridevi P, et al. Toxic epidermal necrolysis: a retrospective study. Int J Dermatol 1997: 36: 923-925. (Pubitemid 28053894)
22. Kardaun S, Jonkman M. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta DermVenereol 2007: 87: 144-148. (Pubitemid 46513200)
23. Engelhardt S, Schurr M, Helgerson R. Toxic epidermal necrolysis. J Burn Care Rehabil 1997: 18: 520-524.
24. Halebian P. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986: 204: 503-512. (Pubitemid 17176768)
25. Chave T, Mortimer N, Sladden M, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005: 153: 241-253. (Pubitemid 41228420)
26. Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg 2005: 58: 504-510. (Pubitemid 40645392)
27. Fischer M, Fiedler E, Marsch W, et al. Antitumor necrosis factor-alpha antibodies (infliximab) in the treatment of a patientwith toxic epidermal necrolysis. Br JDermatol 2002: 146: 707-708. (Pubitemid 34437794)
28. Hunger R, Hunziker T, Buettiker U, et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J All Clin Immunol 2005: 116: 923-924. (Pubitemid 41400562)
29. Al-Shouli S, Abouchala N, Bogusz M, et al. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta DermVenereol 2005: 85: 534-535. (Pubitemid 43087298)
30. Meiss F, Heimbold P, Meykadeh N, et al. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases. J Eur Acad Dermatol Venereol 2007: 21: 717-719. (Pubitemid 46916796)
31. Wojtkiewicz A, Wysocki M, Fortuna J, et al. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm Venereol 2008: 88: 421-421.
32. Gubinelli E, Canzona F, Tonzani T, et al. Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol 2009: 36: 150-153.
33. Sadighha A. Etanercept in the treatment of a patient with acute generalized exanthematous pustulosis/toxic epidermal necrolysis: definition of a new model based on translational research. Int J Dermatol 2009: 48: 913-914.
34. Inamo Y, Okubo T, Wada M, et al. Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Three case reports. Int Arch All Immunol 2002: 127 (1): 89-94. (Pubitemid 34224958)
35. Redondo P, Ruiz de Erenchun F, Iglesias M, et al. Toxic epidermal necrolysis: treatment with pentoxyfylline. Br J Dermatol 1994: 130: 688-689. (Pubitemid 24204719)
36. Clemente GS, Dela Roche C, Escobar C, et al. Pentoxyfylline in toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 1999: 38: 878-879.
37. Redondo P, de Filipe I, de la Pena A, et al. Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis: treatment with n-acetylcysteine. Br J Dermatol 1997: 136: 645-646. (Pubitemid 27160362)
38. Velez A, Moreno J. Toxic epidermal necrolysis treated with n-acetylcysteine. J Am Acad Dermatol 2002: 46: 469-470. (Pubitemid 34225424)
39. Goulden V, Goodfield M. Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis. Br J Dermatol 1996: 135: 305-306. (Pubitemid 26252986)
40. Jarrett P, Rademaker M, Havill J, et al. Toxic epidermal necrolysis treated with cyclosporin and G-CSF. Clin Exp Dermatol 1997: 22: 146-147.
41. Heng M. Efficacy of cyclophosphamide in toxic epidermal necrolysis. clinical and pathophysiologic aspects. J Am Acad Dermatol 1991: 25 (5Pt1): 778-786.
42. Frangiogiannis N, Boridy I, Mazhar M, et al. Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 1996: 89: 1001-1003. (Pubitemid 26347087)
43. Arevalo J, Lorenta J, Gonzalez-Herrada C, et al. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000: 48: 473-478. (Pubitemid 30183110)
44. Aihara Y, Ito R, Ito S, et al. Toxic epidermal necrolysis in a child successfully treated with cyclosporin A and methylprednisolone. Pediatr Int 2007: 49: 659-662. (Pubitemid 47414919)
45. Renfro L, Grant-Kels J, Daman L. Drug-induced toxic epidermal necrolysis treated with cyclosporin. Int J Dermatol 1989: 28: 441-444.
46. Sakellariou G, Koukoudis P, Karpouzas J, et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int J Artif Organs 1991: 14: 634-638.
47. Chaidemenos G, Chrysomallis F, Sombolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 1997: 36: 218-221. (Pubitemid 27208324)
48. Yamada H, Takamori K, Yaguchi H, et al. A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis. Ther Apher 1998: 2: 153-156. (Pubitemid 28311175)
49. Egan C, Grant W, Morris S, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999: 40: 458-461. (Pubitemid 29115308)
50. Bamichas G, Natse T, Christidou F, et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher 2002: 6: 225-228. (Pubitemid 34753566)
51. Furubacke A, Berlin G, Anderson C, et al. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? Intensive Care Med 1999: 25: 1307-1310.
52. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of cd95 with human intravenous immunoglobulin. Science 1998: 282 (5388): 490-493. (Pubitemid 28483679)
53. Phan T, Wong R, Crotty K, et al. Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. Australas J Dermatol 1999: 40: 153-157. (Pubitemid 29374366)
54. Morici M, Galen W, Shetty A, et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. J Rheumatol 2000: 27: 2494-2497.
55. Stella M, Clemente A, Bollero D, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: experience with high-dose intravenous immunoglobulins and topical conservative approach: a retrospective analysis. Burns 2007: 33: 452-459. (Pubitemid 46702386)
56. Tristani-Firouzi P, Petersen M, Saffle J, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002: 47: 548-552.
57. Campione E, Marulli G, Carrozzo A, et al. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta DermVenereol 2003: 83: 430-432. (Pubitemid 37475783)
58. Metry D, Jung P, Levy M. Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics 2003: 112 (6Pt1): 1430-1436. (Pubitemid 37523435)
59. Prins C, Kerdel F, Padilla R, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003: 139 (1): 26-32. (Pubitemid 36091570)
60. Al-Mutari N, Arun J, Osama N, et al. Prospective noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol 2004: 43: 1117-1118.
61. Tan A, Thong B, Yip L, et al. High dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J Dermatol 2005: 32 (1): 1-6. (Pubitemid 40313054)
62. Mangla K, Rastogi S, Goyal P, et al. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol 2005: 71: 398-400. (Pubitemid 41769422)
63. Nasser M, Bitterman-Deutsch O, Nassar F. Intravenous immunoglobulin for treatment of toxic epidermal necrolysis. Am J Med Sci 2005: 329: 95-98. (Pubitemid 40250600)
64. Trent J, Halem M, French L, et al. Toxic epidermal necrolysis and intravenous immunoglobulin: a review. Seminars Cutaneous Medicine Surgery 2006: 25: 91-93. (Pubitemid 44189890)
65. Mittmann N, Chan B, Knowles S, et al. Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol 2006: 7: 359-368. (Pubitemid 46998570)
66. Teo L, Tay Y, Liu T, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options. Singapore Med J 2009: 50 (1): 29-33.
67. Molgo M, Carreno N, Hoyos-Bachiloglu R, et al. Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. review of 15 cases. Rev Med Chil 2009: 137: 383-389.
68. Yang Y, Xu J, Li F, et al. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China. Int J Dermatol 2009: 48: 1122-1128.
69. Bachot N, Revuz J, Roujeau J. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003: 139 (1): 33-36. (Pubitemid 36091571)
70. Brown K, Silver G, Halerz M, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004: 25 (1): 81-88.
71. Shortt R, Gomez M, Mittmann N, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004: 25: 246-255. (Pubitemid 38637782)
72. Pasic S. Intravenous immunoglobulin in toxic epidermal necrolysis. Int J Dermatol 2006: 45: 1117-1118. (Pubitemid 44317142)
73. Faye O, Roujeau J. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIG): clinical experience to date. Drugs 2005: 65: 2085-2090. (Pubitemid 41475790)
74. Schneck J, Fagot J, Sekula P, et al. Effects of treatment on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008: 58 (1): 33-40. (Pubitemid 350298143)
75. Wolff K, Tappeiner G. Treatment of toxic epidermal necrolysis. Arch Dermatol 2003: 139: 85-86.
76. Paquet P, Pierard GE. Topical treatment options for drug-induced toxic epidermal necrolysis (TEN). Expert Opin Pharmacother 2010: 11 (15): 2447-2458.